NCT02101918View on ClinicalTrials.gov

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 18, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Multiple Endocrine Neoplasia Type 1Pancreatic Neuroendocrine Carcinoma
Interventions
RADIATION

Computed Tomography Perfusion Imaging

Undergo computed tomography perfusion imaging

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Ziv-Aflibercept

Given IV

Trial Locations (3)

33607

Moffitt Cancer Center-International Plaza, Tampa

33612

Moffitt Cancer Center, Tampa

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02101918 - Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter